Mahamanjishthadi Kashayam: Composition, Evidence & Safety

TL;DR

Mahamanjishthadi Kashayam is a classical Ayurvedic polyherbal decoction from the Sahasrayoga, about 45 herbs led by manjishtha (Rubia cordifolia), traditionally used for chronic skin disorders and "blood purification." No randomized trial has tested the formula itself. One open-label 2025 study of a four-drug Ayurvedic regimen including it reported psoriasis improvement.

(52 words. Sources: JETIR 2025 review of the formulation; Munjani & Soni 2025, open-label study, n=30.)

What it is

Mahamanjishthadi Kashayam (also spelled Mahamanjishtadi Kwath/Kadha) is a classical polyherbal decoction referenced in the Sahasrayoga, a compendium of traditional Ayurvedic formulations. It is not a single herb: the formula combines some four dozen botanical ingredients, led by Manjishtha, the root of Rubia cordifolia (Indian madder), and including Musta (Cyperus rotundus), Kutaja (Holarrhena antidysenterica), Guduchi (Tinospora cordifolia), Nimba (Azadirachta indica), Haridra (Curcuma longa), Daruharidra (Berberis aristata), Triphala (Haritaki, Vibhitaki, Amalaki), Katuka (Picrorrhiza kurroa), Vacha (Acorus calamus), Khadira (Acacia catechu), Bakuchi (Psoralea corylifolia), and Sariva (Hemidesmus indicus), among others (formulation review, JETIR 2025).

A critical point for reading the evidence: research on any single ingredient, including manjishtha alone, is not evidence for the formula. A decoction of ~45 herbs is a different intervention from any one of its components, and this article keeps the two strictly separate.

Traditional use

In classical Ayurvedic terms the formula is described as raktashodhaka ("blood-purifying": a traditional concept, not a measurable clinical endpoint), kapha-pitta-balancing, and krimighna, with bitter and astringent tastes. Its traditional indications center on chronic skin disorders (kustha: including named subtypes such as kitibha and pama, roughly corresponding to psoriasis-like and eczema-like conditions), non-healing wounds (dustavrana), vatarakta (gout-like joint disorders), and disorders attributed to vitiated blood (JETIR 2025). These are classical indications, not clinical proof: what follows is what has actually been studied.

What modern research says

The formula itself: no randomized trials

No randomized, controlled trial has tested Mahamanjishthadi Kashayam by itself. The published clinical literature consists of an open-label study and case reports in which the formula was one part of a multi-drug Ayurvedic regimen: so its individual contribution cannot be isolated.

Psoriasis: open-label study of a four-drug regimen (2025)

A 2025 open-label, single-group clinical study at a government Ayurveda college hospital treated 30 psoriasis patients (diagnosed in Ayurvedic terms as Ekakushtha) for 6 weeks, with 2 weeks of follow-up, using Mahamanjishthadi Kwatha together with Kaishora Guggulu, Panchatikta Ghrita, and Eranda Taila. Most patients showed marked to moderate improvement, with no reported side effects and good adherence (Munjani & Soni, 2025). Limitations: no control group, no blinding, a combination regimen, and a short follow-up: this is a preliminary signal, not proof.

Case reports (psoriasis, vitiligo)

Individual case reports describe Mahamanjishthadi Kwath/Kashayam as part of broader Ayurvedic management: one plaque-psoriasis case combined it (10 mL twice daily) with Panchatikta Ghrita Guggul and Virechana (therapeutic purgation), reporting a PASI score fall from 29.9 to 3.5 over four months (JAIMS case report). A vitiligo case used 20 mL twice daily within a multi-drug regimen over several months with reported repigmentation (JCDR case report_F(Sh)_QC(SD_IS)_PF1_(VD_OM)_redo_PFA(IS)_PB(VD_IS)_PN(IS).pdf)); and another psoriasis case used 15 mL twice daily alongside other medicines with reported relief of itching and scaling (IJAPC case study). Case reports cannot establish efficacy, and in every case the formula was combined with other treatments.

Single-ingredient research is not formula evidence

Rubia cordifolia (manjishtha) is only one of the formula's ~45 ingredients. Whatever the separate research literature on that single plant shows, none of it tests Mahamanjishthadi Kashayam: so do not read ingredient-level findings as support for the finished formula.

What the evidence does not support (yet)

There is no controlled evidence that Mahamanjishthadi Kashayam treats psoriasis, eczema, vitiligo, or any other condition. Traditional use for chronic skin disorders is not clinical proof.

Dosage

There is no established or pharmacopoeially verified dose accessible for this article, and no trial has validated a dose. The published case reports describe regimens of 10–20 mL of the decoction twice daily with warm water before food: always as one element of a multi-drug Ayurvedic protocol, not as a standalone recommendation (JAIMS; JCDR_F(Sh)_QC(SD_IS)_PF1_(VD_OM)_redo_PFA(IS)_PB(VD_IS)_PN(IS).pdf)). These are reported clinical regimens, not personal dosing guidance. Use only under the supervision of a qualified Ayurvedic practitioner.

Safety & contraindications

The 2025 open-label study reported no side effects over 6 weeks of the four-drug regimen, but that is a small, short, uncontrolled observation: not a safety profile for the formula (Munjani & Soni, 2025). Beyond this, there are no human safety trials of Mahamanjishthadi Kashayam: no long-term data, no verified interaction data, and no data in pregnancy or breastfeeding. The formula contains some four dozen herbs, several of them pharmacologically active (including Picrorrhiza kurroa and Acorus calamus among the listed ingredients), which makes unsupervised use inadvisable. Avoid during pregnancy and breastfeeding, and discuss use with your clinician if you take prescription medicines.

FAQs

What is Mahamanjishthadi Kashayam?

A classical Ayurvedic polyherbal decoction from the Sahasrayoga, about 45 herbs led by manjishtha (Rubia cordifolia), traditionally used for chronic skin disorders and "blood purification" (JETIR 2025). It is a formulation, not a single herb.

Does Mahamanjishthadi work for psoriasis?

Unproven. One 2025 open-label study of 30 patients reported marked-to-moderate improvement using the formula as part of a four-drug Ayurvedic regimen: but with no control group, the formula's own effect cannot be isolated (Munjani & Soni, 2025).

Is Mahamanjishthadi the same as manjishtha?

No. Manjishtha (Rubia cordifolia) is one ingredient, the lead herb, in a ~45-herb formula. Research on manjishtha alone is not evidence for Mahamanjishthadi Kashayam.

What is the dose of Mahamanjishthadi Kashayam?

There is no established dose. Published case reports describe 10–20 mL twice daily with warm water before food, always within multi-drug Ayurvedic protocols: reported regimens, not recommendations. Use only under qualified practitioner supervision.

Is Mahamanjishthadi safe?

No human safety trials exist beyond a small 6-week open-label observation reporting no side effects. With ~45 ingredients and no long-term or pregnancy data, unsupervised use is inadvisable.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.